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Mutations of the breast and ovarian cancer susceptibility gene 1 (BRCA1) account for
about 40–45% of hereditary breast cancer cases. Moreover, a significant fraction of
sporadic (non-hereditary) breast and ovarian cancers exhibit reduced or absent expression
of the BRCA1 protein, suggesting an additional role for BRCA1 in sporadic cancers.
BRCA1 follows the classic pattern of a highly penetrant Knudsen-type tumor suppressor
gene in which one allele is inactivated through a germ-line mutation and the other is
mutated or deleted within the tumor. BRCA1 is a multi-functional protein but it is not
fully understood which function(s) is (are) most important for tumor suppression, nor is
it clear why BRCA1-mutations confer a high risk for breast and ovarian cancers and not a
broad spectrum of tumor types. Here, we will review BRCA1 functions in the DNA damage
response (DDR), which are likely to contribute to tumor suppression. In the process, we
will highlight some of the controversies and unresolved issues in the field. We will also
describe a recently identified and under-investigated role for BRCA1 in the regulation of
telomeres and the implications of this role in the DDR and cancer suppression.
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INTRODUCTION
The breast and ovarian cancer susceptibility gene 1 (BRCA1) on
chromosome 17q21 was identified and cloned in 1994 by Miki
et al. (1994), 1 year before the reported cloning of a second breast
cancer susceptibility gene (BRCA2) on chromosome 13q12-13 by
Wooster et al. (1995). The BRCA1 gene fits the classical Knudsen
“two hit” model of a tumor suppressor gene. This model was
developed by Dr. Alfred Knudsen, Jr. in 1971 and was first applied
to understand the genetics of retinoblastoma, a tumor of the
cells of the retina in the eye that occurs in very young children.
According to this model, a cell requires two “hits” (mutations),
one in each allele of a tumor suppressor gene (e.g., RB1, the
retinoblastoma susceptibility gene) for a cancer to develop. In
hereditary cancers, the first “hit” is a germ-linemutation, which is
thus present in all somatic cells. The second “hit” (often the dele-
tion of a portion of the chromosome containing the wild-type
allele) occurs only in somatic cells within the target tissue, and
leads to cancer. In thismodel, the inheritance pattern is autosomal
dominant (since only one mutant allele is inherited). However, at
the molecular level, the tumor exhibits a “recessive” pattern, since
both alleles must be inactivated for a tumor to occur. In the case
of BRCA1, women inherit one mutant allele and one wild-type
allele; but in nearly all tumors that develop in BRCA1-mutation
carriers, the wild-type allele is lost (Merajver et al., 1995), leaving
no functional BRCA1 in the tumor cells.
Although inherited BRCA1-mutations account for a very small
proportion of all breast cancers (2.5–5%), a significant propor-
tion of the much larger group of sporadic (non-hereditary) breast
cancers (30–40%) exhibit absent or significantly reduced levels of
BRCA1 protein, suggesting that loss of BRCA1 function whether
by epigenetic silencing, mutation, or other mechanisms is a com-
mon component in the pathogenesis of sporadic breast cancer
(Rice et al., 1998; Taylor et al., 1998; Wilson et al., 1999; Esteller
et al., 2000; Staff et al., 2003). Consistent with the Knudsenmodel,
inactivating mutations of both BRCA1 alleles are uncommon in
sporadic breast cancers, since the probability of two acquired hits
in a somatic cell is much lower than that of a second hit in a cell
that has already acquired the first hit by inheritance.
THE HUMAN BRCA1 GENE AND PROTEIN
The BRCA1 gene contains 24 exons, 22 of which are coding
exons and 2 of which are non-coding (Miki et al., 1994). Exon
11 is the largest exon and encodes about 60% of the protein.
The BRCA1 protein consists of 1863 amino acids, migrates on
SDS-PAGE at a molecular mass (Mr) corresponding to 220 kDa,
and does not show significant structural homology to other
human proteins with the exception of an N-terminal RING
domain (amino acid 20–64) and a C-terminal acidic domain
(TAD). This TAD can mediate transcription when ligated to
a suitable DNA-binding domain (Monteiro et al., 1996). The
C-terminal TAD of BRCA1 contains a tandem repeat of 95
amino acids each called a BRCA1-associated C-terminal (BRCT)
domain that is homologous to similar domains found within
various DNA repair and cell cycle checkpoint proteins (Bork
et al., 1997) (see Figure 1). The BRCT domains were subse-
quently found to be phosphoprotein-binding modules that bind
to specific phosphoserine- or phosphotyrosine-containing motifs
and are involved in the processes of DNA damage signaling
and repair (Manke et al., 2003). The BRCA1 RING domain
was found to interact with another RING-containing protein
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FIGURE 1 | Breast and ovarian cancer susceptibility gene 1 protein
interactions that contribute to its role in the DNA damage response. In
response to DNA damage, BRCA1 is phosphorylated at various sites by
several kinases (e.g., ATM, CHK2, and/or ATR) and forms several different
types of complexes that are recruited to the sites of DNA damage through
various mechanisms. The roles of these complexes in DNA damage signaling
and repair are only partially understood. The formation of these BRCA1
complexes is dependent upon the mutually exclusive interactions of its BRCT
domains with phosphorylated motifs within Abraxis, BACH1, or CtIP. BRCA1
functions to recruit BRCA2 to DNA damage sites through an intermediary
protein, PALB2 (partner and localizer of BRCA2). The interaction of the
BRCA1 N-terminal RING domain with its binding partner BARD1 is required
for tumor suppression, since BRCA1-mutations that disrupt this interaction
lead to cancer.
BRCA1-associated ring domain 1 (BARD1) protein to mediate
an enzymatic function as an E3 ubiquitin ligase (to be discussed
below in detail). The BRCA1 protein also contains functional
nuclear import and nuclear export signals, suggesting that it may
shuttle between the nucleus and cytoplasm, although it seems that
most BRCA1 functions occur within the nucleus (Rodríguez and
Henderson, 2000).
Breast and ovarian cancer susceptibility gene 1 has been
found to regulate the activity of a variety of different transcrip-
tion factors although BRCA1 is not itself a sequence-specific
DNA-binding transcription factor. The usual paradigm is that
BRCA1 binds directly to many different transcription factors
[e.g., p53, estrogen receptor, progesterone receptor, androgen
receptor, STAT1, c-Myc, NF-κB, octamer-binding transcription
factor 1 (OCT1), and others], while other portions of the BRCA1
molecule make contact with components of the basal transcrip-
tion machinery (RNA polymerase II holoenzyme) and/or with
components of chromatin remodeling complexes (reviewed in
Rosen et al., 2006). In this context, BRCA1 functions as a tran-
scriptional co-regulator that may either stimulate (e.g., p53,
androgen receptor, OCT1) or inhibit (e.g., estrogen receptor, pro-
gesterone receptor, c-Myc) transcriptional activity. Thus, some
BRCA1 functions are linked to the regulation of transcription,
although which of these may contribute to tumor suppression
remains unclear to date.
ATM-DEPENDENT SIGNALING AND THE DNA DAMAGE
RESPONSE
Ataxia-telangiectasia (A-T) is an autosomal recessive hereditary
disorder characterized by neurodegeneration (including cerebel-
lar ataxia), immunodeficiency, predisposition to develop cancer,
skin abnormalities, and increased sensitivity to ionizing radiation
(IR). A-T is due to mutation of the ATM (A-T mutated) gene,
the protein product of which functions as a master regulator
of the DNA damage response (DDR) (Lavin and Kozlov, 2007).
ATM-deficient cells exhibit hypersensitivity to IR and defects in
DNA damage-responsive cell cycle checkpoints (see below). The
prototypic activator of ATM is the DNA double-strand break
(DSB) due to IR. In the model shown in Figure 2A, the broken
DNA ends are recognized by the MRN complex of three pro-
teins [MRE11-RAD-50-Nijmegen breakage syndrome 1 (NBS1)],
which functions as a DNA damage sensor and translocates to the
site of the DSB (Lee and Paull, 2005). ATM normally exists as an
inactive dimer which is maintained in that state by the protein
serine/threonine phosphatase PP2A (Bakkenist and Kastan, 2003;
Goodarzi et al., 2004). In response to DNA damage, PP2A disso-
ciates from ATM, allowing autophosphorylation on S1981 (and
several other residues) and conversion to an active monomer,
which is facilitated by physical contact between ATM and the
MRN complex at the site of the DSB.
In the context of ATM activation at the sites of DSBs, BRCA1-
associated protein required for ATM activation-1 (BAAT1) serves
to prevent the premature dissipation of ATM activity by bind-
ing to the activated ATM protein and preventing the pre-
mature dephosphorylation of ATM at serine-1981 by PP2A
(Aglipay et al., 2006). Further activation of ATM is medi-
ated by the chromatin-binding acetyltransferase TIP60 (Sun
et al., 2010). TIP60 targets ATM by binding to trimethylated
histones near the DSB and acetylating ATM within its PIKK
regulatory domain (PRD), which lies adjacent to its kinase
domain.
The scheme described above and illustrated in Figure 2A con-
stitutes the classical activation mechanism for ATM in the setting
of DNA damage. Recent studies indicate a second mechanism
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FIGURE 2 | ATM activation by ionizing radiation (IR) vs. oxidative
stress. (A) In IR-induced activation, the MRN complex, a DNA damage
sensor, is recruited to DSBs; and MRN then recruits ATM. In
undamaged cells, ATM is a dimer held in the inactive state by PP2A.
After IR, PP2A dissociates from ATM, allowing autophosphorylation on
S1981 and conversion to a monomer at the MRN/DSB site. The protein
BAAT1 binds to activated ATM and prevents dephosphorylation by
PP2A. Another step in ATM activation involves binding of TIP60 to
chromatin near the DSB and acetylation of ATM, which is required for
its full activation. (B) In response to oxidative stress, ATM is directly
oxidized, forming a disulfide-linked dimer, which is phosphorylated on
S1981 and activated.
for ATM activation due to oxidative stress (Guo et al., 2010;
Ditch and Paull, 2012). Here, ATM, which also mediates a cyto-
protective response to oxidative stress, is activated by a direct
mechanism through oxidation of the ATM protein, which does
not require the MRN complex (Figure 2B). The result is an active
ATM dimer held together by a disulfide linkage that contains two
phosphorylated serine-1981 residues.
ATM DOWNSTREAM SIGNALING: RECRUITMENT OF BRCA1
TO DSBs
A large number of different substrates for ATM have been iden-
tified (Kastan and Lim, 2000), but herein we will focus on those
most closely involved in the recruitment of BRCA1 to the sites
of DSBs. In the setting of DNA damage, ATM very rapidly phos-
phorylates a nearby variant histone (H2AX) on serine-139 (the
phosphorylated form of H2AX is known as γ-H2AX), although
it is clear that other kinases (e.g., ATM and Rad5-related, ATR)
in different contexts can also phosphorylate H2AX (Burma et al.,
2001; Wang et al., 2005). Phosphorylated H2AX is recognized by
mediator of DNA damage checkpoint protein 1 (MDC1), allow-
ing the recruitment of MDC1 to the sites of DSBs (Stewart et al.,
2003; Lee et al., 2005). These events occur very rapidly (within
seconds) following the formation of a DSB. MDC1, like H2AX
is also a substrate for the ATM kinase. MDC1 serves as a scaf-
fold for the accumulation of other DDR proteins at DNA damage
sites and also functions to amplify the DDR (Lou et al., 2006).
The proposed mechanism is that MDC1 bound to γ-H2AX can
then recruit a second ATM, through the interaction of ATM with
the FHA domain of MDC1. This allows phosphorylation of a
second H2AX molecule and subsequent recruitment of another
MDC1 molecule and so on (Lou et al., 2006; Yan and Jetten,
2008). Besides ATM, MDC1, and γ-H2AX, the MRN complex
is also involved in this amplification process, through a mecha-
nism in which MDC1 is phosphorylated by casein kinase 2 (CK2)
and NBS1 binds to MDC1 through its phosphorylated CK2 site
(Spycher et al., 2008). These mechanisms allow extension of the
DNA damage signal up to 1Mb upstream and downstream of the
original break site and explains why ionizing radiation-induced
DNA repair foci (IRIF) can be easily detected by immunofluores-
cence microscopy (Costes et al., 2010).
Although BRCA1 is phosphorylated relatively rapidly in
response to DSBs (see below), its recruitment in large quantities
to IRIF is usually delayed (>1 h). Recent progress has eluci-
dated several mechanisms by which BRCA1 becomes localized
to IRIF (Kolas et al., 2007; Sobhian et al., 2007; Yan and Jetten,
2008; Strauss et al., 2011; Campbell et al., 2012; Mattiroli et al.,
2012; Zhang et al., 2012). Two mechanisms are illustrated in
Figure 3. In one scheme, the E3 ubiquitin ligase RNF8 binds to
MDC1 in a phosphorylation-dependent interaction and along
with an associated E2 ubiquitin-conjugating enzyme (Ubc13)
ubiquitinates MDC1 on lysine-1977 of MDC1 (Figure 3A). Then
RAP80, through its ubiquitin-interacting motif (UIM) binds to
ubiquitinated MDC1. RAP80, a component of BRCA1 complex
A (Figure 1), recruits BRCA1 to the IRIF through the adap-
tor protein Abraxis, which interacts directly with BRCA1. This
interaction is mediated through binding of the BRCT domain
with the pSPXF [phosphoserine-proline–(X = any amino acid)–
phenylalanine]. Other components of BRCA1 complex A include
BARD1, BRCC36, BRCC45, and NDA1 (MERIT40) (Fong et al.,
2009; Wang, 2012). In the second scheme, RNF8 and a second
ubiquitin ligase (RNF168) mediate a specific polyubiquitination
of a nearbyH2AX orH2Amolecule through Ubc13, and the ubiq-
uitin chain is recognized by the UIM of RAP80, leading to the
recruitment of the BRCA1 complex A (Figure 3B). The possible
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FIGURE 3 | Recruitment of BRCA1 to sites of double-strand DNA breaks.
Two possible mechanisms by which the BRCA1 complex A can be recruited
to ionizing radiation-induced foci (IRIF) are illustrated in (A,B). Both involve
post-translational modifications of DDR proteins, including phosphorylation
and ubiquitination. In (A), the RNF8/Ubc13 complex ubiquitinates MDC1, and
the ubiquitin-interacting motif (UIM) of RAP80 interacts with ubiquitinated
MDC1. In (B), RNF8/Ubc13 polyubiquitinates a nearby histone H2AX and the
UIM of RAP80 interacts with the ubiquitinated H2AX protein. In each case,
phosphorylated Abraxis interacts with the BRCT domain of BRCA1 and the
RAP80 protein, thus recruiting BRCA1 to the site of the DSB.
functions of the BRCA1 complexes A, B, and C are considered
below. We note here that the recruitment of these complexes to
DNA damage sites is mutually exclusive, suggesting that the com-
plexes function during different phases of the cell cycle and/or at
different times during the DDR.
BRCA1 FUNCTIONSWITHIN THE DDR
In the context of the DDR, early clues to BRCA1 gene func-
tion came from studies of Brca1-deficient fibroblasts and tumors,
which exhibited evidence of extensive genomic instability, includ-
ing a pattern of aneuploidy, centrosomal amplification, and chro-
mosomal aberrations (Tirkkonen et al., 1997; Xu et al., 1999;
Weaver et al., 2002). Consistent with these findings, Scully et al.
(1997a,b) had reported that: (1) BRCA1 colocalizes with Rad51,
a DNA recombinase, in nuclear foci during S-phase; and (2)
following DNA damage, BRCA1 became phosphorylated and
translocated to PCNA-positiveDNA structures containing Rad51,
and BARD1. Taken together, these findings suggested a role
for BRCA1 as a caretaker gene involved in the monitoring and
maintenance of genomic integrity. Other studies indicated that
BRCA1-deficient cells showed increased sensitivity to IR (Shen
et al., 1998; Scully et al., 1999; Ruffner et al., 2001). Since cell death
following IR is mainly due to incomplete repair of DNA DSBs,
these findings suggest a role for BRCA1 in the DDR pathways that
are activated in response to DSBs.
ROLE OF BRCA1 IN DNA DAMAGE-ACTIVATED CELL CYCLE
CHECKPOINTS
Further research suggested specific roles for BRCA1 in response
to DNA damage induced by IR. Thus, BRCA1 was found to be
required for several DNA damage-responsive cell cycle check-
points. These checkpoints are activated in response to DNA
damage (e.g., DSBs) and function to block cell cycle progression
in order to allow the repair of DNA lesions, so the damage is not
propagated and passed on to daughter cells. One such BRCA1-
regulated cell cycle checkpoint is the G2/M checkpoint (Xu et al.,
2001; Yarden et al., 2002). Here, BRCA1 was found to be essential
for the activation of checkpoint kinase 1 (CHK1), a key effector of
G2/M arrest (Yarden et al., 2002). Both ATM (A-T mutated) and
BRCA1 were found to be required for the IR-induced S-phase as
well G2 checkpoints; and a specific phosphorylation of BRCA1
by ATM at serine-1423 was required for activation of the G2 the
checkpoint (Xu et al., 2001). BRCA1, as well as the ATR protein,
were also found to participate in another G2 cell cycle checkpoint
known as the decatenation checkpoint (Deming et al., 2001).
This checkpoint monitors the status of chromatid unwinding and
delays cell entry into mitosis until the chromatids are sufficiently
unwound (decatenated), in order to prevent chromosomal stress
that might lead to aneuploidy or polyploidy.
The DNA damage-induced S-phase checkpoint results in inhi-
bition of replication initiation in response to DNA damage. A
defect in this checkpoint results in continued DNA synthesis,
also called radioresistant DNA synthesis following IR. This check-
point was found to require an ATM-dependent phosphorylation
of BRCA1 on serine-1387 as well as a functional NBS1 (Xu
et al., 2002). In addition to DNA damage-responsive checkpoints,
several studies indicate that BRCA1 also regulates the mitotic
spindle checkpoint by regulating gene expression associated with
orderly progression through mitosis (Wang et al., 2004; Bae et al.,
2005). Here, BRCA1 deficiency caused a defect in the spindle
checkpoint (which ensures orderly separation of chromatids) as
well as a defect in cytokinesis that resulted in accumulation of
multinucleated cells, Several recent studies suggest that a CHK2-
mediated phosphorylation of BRCA1 (see Figure 1) is required
for orderly assembly of themitotic spindle and proper segregation
of chromosomes (Stolz et al., 2010a,b).
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Finally, a role for BRCA1 in the IR-induced G1/S checkpoint,
which blocks entry of cells containing chromosomal breaks into
S-phase, has been demonstrated. Here, in response to IR, ATM
phos-phorylates BRCA1 on serine-1423 and serine-1524, which
allows the efficient ATM-mediated phosphorylation of p53 on
serine-15, activation of p53 transcriptional activity, and subsequent
expression of the cell cycle inhibitor p21 (Fabbro et al., 2004). In
this study, the BRCA1/BARD1 complex was required for the ATM
phosphorylation of p53 and subsequent G1/S cell cycle arrest.
ROLE OF BRCA1 IN HOMOLOGY-DIRECTED DNA REPAIR
Double-strand breaks can be repaired by two major pathways:
(1) homology-directed repair (HDR; also called homologous
recombination); or (2) non-homologous end joining (NHEJ)
(Symington and Gautier, 2011). Here, we will consider the role of
BRCA1 in HDR, while its putative role in NHEJ will be discussed
in the next section. HDR can only occur during S-phase and
G2-phase, because the homologous strand of the corresponding
sister chromatid is required as a template for repair-related DNA
synthesis. This form of DSB repair is usually considered to be
error-free, and thus a mechanism for maintenance of genomic
integrity (but see below). Moynahan et al. (1999) first described a
major role for BRCA1 in HDR based on the finding that a Brca1-
deficient reporter mouse embryonic stem (ES) cell line failed
to accurately repair a chromosomal DSB created by the I-Sce 1
endonuclease. In related studies, the same group demonstrated
that BRCA2was also required forHDRand that the defect inHDR
in Brca1-deficient cells could be corrected by either expression of
a wild-type BRCA1 transgene or correction of one mutated Brca1
allele through gene targeting (Moynahan et al., 2001). While these
studies definitively establish a role for BRCA1 in HDR, they do
not address its biochemical function in HDR. One clue to this
function is the demonstration of a requirement for an ATPase-
competent RAD51 protein for HDR, which was not surprising
since RAD51 is the mammalian homolog of the bacterial DNA
recombinase RecA (Stark et al., 2002). It has been suggested that
HDR is the major tumor suppressor function for both BRCA1
and BRCA2, since a deficiency in HDR leads to increased levels
of NHEJ and single-strand annealing (SSA), both of which are
error-prone processes that lead to genomic instability.
While the process of homologous recombination has been exten-
sively investigated over several decades, the role of BRCA1 in this
process has not been fully worked out. A review of this process
and its potential role in tumor suppression can be found elsewhere
(Moynahan and Jasin, 2010). The first step in HDR involves the
5′–3′ end resection of DNA starting at the site of the DSB. This
resection creates a segment of single-stranded DNA (ssDNA) that
can then invade the sister chromatid and pair with the complimen-
tary DNA strand, allowing the initiation of repair. These resected
ends can then be utilized by RAD51, which catalyzes the crossover
reaction. In this regard, it is thought that BRCA1 in complex
with the CtBP-interacting protein (CtIP; designated “complex C”)
(Figure 1) facilitates the end resection by allowing the recruitment
of replication protein A (RPA), a ssDNA-biding protein (Sartori
et al., 2007; Buis et al., 2012; Escribano-Díaz et al., 2013). The
phosphorylation of CtIP that is required for its recognition of
and binding to the BRCT domains of BRCA1 is mediated by
cyclin-dependent kinase 2 (CDK2) and is facilitated by MRE11, a
component of the MRN protein complex (Buis et al., 2012); and
both theMRN complex and CtIP were found to contribute to DNA
end resection at the sites of DSBs (Sartori et al., 2007). Complex
C also participates in the G2/M cell cycle checkpoint (Yu et al.,
2006).
After end resection and recruitment of RPA to the newly
created ssDNA, the recombinase RAD51 is recruited to the
resected ends. The recruitment of RAD51 is dependent upon
other proteins, including RAD54 and BRCA2 (which directly
binds multiple copies of RAD51 copies and regulates their activ-
ity) (Gudmundsdottir and Ashworth, 2006). Partner and localizer
of BRCA2 (PALB2) is required for the localization of BRCA2 at
DNA damage sites and its participation in HDR and, in turn,
PALB2 binds directly to BRCA1, suggesting that it functions as an
adapter between BRCA1 and BRCA2 during the process of HDR
(Sy et al., 2009; Zhang et al., 2009; Buisson and Masson, 2012)
(see Figure 1). The final steps in DSB repair by HDR involves
the formation two Holliday junctions, which are then resolved
without crossover, restoring the DNA to its original condition
without sequence abnormalities (Moynahan and Jasin, 2010). It
is noted here that while both BRCA1 and BRCA2 function in the
HDR pathway, the role of BRCA1 in the DDR is broader than
that of BRCA2, since BRCA1 also mediates cell cycle checkpoints.
FUNCTIONS OF BRCA1 COMPLEXES A, B, AND C
Although HDR is generally considered to be an error-free process,
an aberrant error-prone form of homologous recombination called
“hyper homologous recombination” (HHR) has been described
(Harris and Khanna, 2011; Dever et al., 2012). HHR was observed
in the presence of mutant forms of BRCA1 (e.g., M1775R) that
disrupt the interaction of the BRCT domain with phosphopeptide
sequences or when components of complex A (Abraxas, RAP80,
or BRCC36) were knocked down (Figure 1). It has been suggested
that BRCA1 complex A functions, in part, as a de-ubiquitinating
complex to limit end resection during the early stages of HDR
to prevent excessive accumulation of RAD51 and RPA on the
invading DNA strand. Other studies indicate that complex A also
participates in the G2/M cell cycle checkpoint and in localizing
BRCA1 to IRIF (Kim et al., 2007a,b; Wang et al., 2007a).
The BRCA1 complex B consists of BRCA1 and BACH1 (BRCT
helicase; also known as BRIT and FANCJ) and is formed by
the interaction of the BRCA1 BRCT with phosphoserine-990 of
BACH1, which is part of a pSPXF motif (Cantor et al., 2004;
Peng et al., 2006; Kumaraswamy and Shiekhattar, 2007; Gong
et al., 2010; Tomimatsu et al., 2012). The function of complex
B is not as clear, but it has been suggested that complex B is
required for orderly progression through S-phase, including the
bypassing of stalled replication forks, and also serves a DNA repair
function that is notwell defined. ComplexC (BRCA1-CtIP-MRN)
is formed through the interaction of the BRCA1 BRCT domain
with phosphoserine-327 of CtIP, which is also part of a pSPXF
motif. This complex is thought to stimulate DNA end resection
byMRE11 during DNA repair by HDR (reviewed inWang, 2012).
However, another nuclease, EXO1,mayplay amore important role
in DNA end resection duringDSB repair (Tomimatsu et al., 2012).
Knockdownof components of complexA orC cause a defect in the
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G2/M cell cycle checkpoint, but the defect created by disruption
of complex C is more mild than that created by knockdown of
complexA.Themoleculardetailsofhowthesecomplexes function,
their precise roles in the maintenance of genomic integrity, and
the mechanisms by which they are assembled and disassembled
remain to be determined. Additional information on the BRCA1
complexes and their significance can be found elsewhere (Wang,
2012).
ROLE OF BRCA1 IN NON-HOMOLOGOUS END JOINING
Non-homologous end joining involves a very different set of
proteins from HDR [e.g., Artemis, XRCC4, DNA polymerase
lambda, DNA ligase IV (LIG4), and DNA-dependent protein
kinase (DNA-PK)]and,unlikeHDR,occurspredominantlyduring
G1 and less so in S-phase or G2 (Lieber, 2010; Dever et al., 2012).
HDR cannot occur during G1, because a homologous segment of
DNA that can act as a template for repair synthesis is unavailable in
G1. The significance of this process is that it can be an error-prone
process because of modification of the broken DNA ends, which
can result in short or longer deletions. With regard to the DDR,
cells defective for NHEJ show hypersensitivity to IR, suggesting
that NHEJ is a major pathway for repair of DSBs generated
by IR. The literature on the putative role of BRCA1 in NHEJ is
unsettled, because several studies suggest a requirement forBRCA1
in NHEJ (Baldeyron et al., 2002; Zhong et al., 2002a,b; Bau et al.,
2004), while others find no defect in NHEJ in BRCA1-deficient
cells (Moynahan et al., 1999; Wang et al., 2001; Mérel et al.,
2002). While the role of BRCA1 in NHEJ remains controversial,
a suggested explanation is that there are several forms of NHEJ,
including one that is error-prone and another that is relatively
precise; andBRCA1onlypromotes theprecise end joining (Durant
and Nickoloff, 2005; Gudmundsdottir and Ashworth, 2006). The
presumed mechanism is that BRCA1, when bound to DNA,
inhibits the nuclease activity of MRE11 or the MRN complex,
thus limiting DNA end resection (Durant and Nickoloff, 2005).
The participation of BRCA1 in the choice and execution ofDSB
DNArepair pathways is illustrated inFigure 4. Recent studies have
identified a cell cycle-dependent mechanism that underlies the
DNA DSB repair pathway choice. p53 Binding protein 1 (53BP1),
when phosphorylated by ATM, binds to RAP1-interactibg factor 1
(RIF1) and recruits RIF1 to DSB sites, where it inhibits 5′ end
resection required for HDR, thus promoting the NHEJ pathway.
In contrast, BRCA1 promotes 5′ end resection and thus HDR
(Escribano-Díaz et al., 2013; Feng et al., 2013). BRCA1 expression
is normally low in G1 and increases significantly during S-phase
andG2. The accumulation of BRCA1during S andG2 counteracts
the ability of 53BP1-RIF1 to stimulate NHEJ. In contrast, when
BRCA1 levels are low during G1, 53BP1-RIF1 accumulate at DSBs
unopposed by BRCA1, resulting in NHEJ being the predominant
pathway for DSB reverse during G1.
BRCA1/BARD1 AND ITS UBIQUITIN LIGASE FUNCTION
Breast and ovarian cancer susceptibility gene 1-associated ring
domain 1 was first identified as a RING domain protein that
interacts and colocalizes with BRCA1 through a RING: RING
interaction involving the N-termini of each protein (Wu et al.,
1996; Jin et al., 1997) (Figure 1). Several cancer-associated point
FIGURE 4 | Double-strand break repair by homology-directed repair
(HDR) or non-homologous end joining (NHEJ). In response to IR, the
MRN complex recognizes and binds to the broken ends of DNA at DSBs.
DSB repair can occur by NHEJ or HDR, depending upon the phase of the
cell cycle and the relative levels of BRCA1 vs. 53BP1 which has been
phosphorylated by ATM and is complexed with RIF1. Some of the proteins
involved in NHEJ and HDR are shown in the boxes. In addition to HDR,
BRCA1 may participate in one subtype of NHEJ, but the role of BRCA1 in
NHEJ is still not certain.
mutations of the RING domain of BRCA1 (e.g., Cys61Gly and
Cys64Gly) disrupted the BRCA1: BARD1 interaction, suggest-
ing that this interaction contributes to BRCA1-dependent tumor
suppression. An early functional study suggested that BARD1
in association with CstF-50 plays a role in regulation of RNA
processing during transcription by inhibiting polyadenylation
(Kleiman and Manley, 1999); and a subsequent study suggested
that this function may be linked to DNA repair (Kleiman and
Manley, 2001). A significant advance in understanding the phys-
iologic importance of the BRCA1: BARD1 interaction was the
finding that the BRCA1: BARD1 heterodimer functions as an E3
ubiquitin ligase and that this ubiquitin ligase activity was abol-
ished by cancer-associated mutations within the BRCA1 RING
domain (Brzovic et al., 2001; Hashizume et al., 2001). These
findings led to the hypothesis that many of the functions of
BRCA1, including its tumor suppressor activity, were due to or
required the ubiquitin ligase activity of the BRCA1: BARD1 com-
plex (Baer and Ludwig, 2002). Further study suggested that the
BARD1 interaction with BRCA1 is required for HDR of chromo-
somal breaks (Westermark et al., 2003). This finding coupled to
the observation of cancer-associated BRCA1-mutations that dis-
rupt the association of BRCA1 with the E2 ubiquitin-conjugating
enzyme UbcH5 (Morris et al., 2006) and the finding that cancer-
associated RING domain mutations of BRCA1 that disrupt the
ubiquitin ligase function cause hypersensitivity to IR (Ruffner
et al., 2001). These considerations led to a great interest in iden-
tifying the in vivo targets of the BRCA1: BARD1 ubiquitin ligase
(Wu et al., 2008).
Then, in 2008, Ludwig and his colleagues generated an isogenic
set of murine ES cells that expressed either wild-type Brca1 or
a mutant Brca1 (I26A) that lacks E3 ubiquitin ligase activity but
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retains the ability to bind to Bard1 (Reid et al., 2008). Surprisingly,
not only were the Brca1 I26A mutant ES cells viable, but they
also exhibited normal sensitivity to the DNA cross-linking agent
mit-omycin C, formed RAD51 foci in response to IR, and exhibited
wild-type rates ofHDR (Reid et al., 2008). These findings challenged
the prevailing view that the BRCA1: BARD1 E3 ubiquitin ligase
activity, the only knownenzymatic functionofBRCA1,was required
for most major functions of BRCA1 thought to be critical for
tumor suppression. In a subsequent study, the same investigators
demonstrated that transgenic mice homozygous for mutant Brca1
I26A targeted to specific tissues (e.g., pancreas or mammary gland)
suppressed tumor formation to the same degree as wild-type Brca1;
whereas a Brca1-mutation of the BRCT domain that abrogated
phosphoprotein-binding (S1598F) conferred a high rate of tumor
formation in the same genetic models (Shakya et al., 2011). The
investigators concluded that the ubiquitin ligase function of BRCA1
was dispensable for tumor suppression, while the recognition of
phosphoproteins by the BRCT domains of BRCA1 was essential
for suppression of tumor formation.
These findings have still not finally settled the question of the
role of the BRCA1 ubiquitin ligase function in tumor suppression.
For example, it was recently reported that BRCA1 normally plays
a major role in repressing satellite DNA (Zhu et al., 2011). Satellite
DNA consists of long stretches of non-coding DNA characterized
by tandemly repeated sequences; and it is a major component
of heterochromatin. In this study, BRCA1 deficiency led to the
loss of transcriptional repression of satellite DNA in mouse mam-
mary tumors, human breast cancers, and cultured cells and to
loss of ubiquitinated histone H2A within the satellite repeats.
Furthermore, BRCA1 was shown to bind to satellite DNA and
ubiquitinate H2A. The BRCA1-deficient phenotype was reversed
by ectopic expression of an H2A-ubiquitin protein. Conversely,
this phenotype (including genomic instability associated with
defects in HDR and cell cycle checkpoints) was reproduced by the
ectopic expression of satellite RNA. The authors’ conclusion that
most BRCA1 tumor suppressor functions are due to its role in the
maintenance of heterochromatin structure (Zhu et al., 2011) is
inconsistentwith the idea that theBRCA1ubiquitin ligase function
is dispensable for tumor suppression (Shakya et al., 2011).
Indirect evidence regarding BRCA1 tumor suppressor function
comes from a study by Gayther et al. (1995) who described a
genotype-phenotype correlation with location of the mutation
within the BRCA1 gene, in BRCA1 breast and/or ovarian cancer
families. Examinationof the ratioofbreast/ovarian cancer revealed
that mutations that mapped to the N-terminus of the BRCA1
protein (including missense mutations and protein-truncating
mutations that deleted the BRCT domains) exhibited a higher
ratio of breast/ovarian cancers than didmutationsmapping to the
C-terminal portion of theBRCA1 gene. Thesefindings suggest that
BRCA1 proteins missing the BRCT domains (and thus defective
for HDR) can still suppress development of ovarian cancer. Other
interpretations of these data are possible, but they do suggest
differences in the mechanisms for development of breast vs.
ovarian cancer in BRCA1-mutation carriers.
Moreover, the idea that BRCA1 deficiency causes cancer solely
due to genomic instability associated with the loss ofHDR and cell
cycle checkpoints does not account for the limited spectrum of
tumor types observed in BRCA1-mutation carriers. Thus, a study
of nearly 700 BRCA1 families indicates that breast and ovarian
cancers are by far the most common, while there is a higher than
expected risk in several additional hormonally related cancers,
including cervical cancer, uterine cancer, and prostate cancers
in younger men (Thompson et al., 2002). These considerations
suggestthatBRCA1exertsanotherfunction(s),perhapsendocrine-
related, that collaborates with its role in maintenance of genomic
integrity to explain why BRCA1-mutations lead to a specific set
of tumor types. Thus, BRCA1 was found to inhibit estrogen
receptor activity, both in cultured cells and mouse models; and
accumulating evidence suggest that BRCA1-related tumorigene-
sis is a hormonally responsive process, both in mice and humans
(reviewed in Rosen et al., 2005).
Finally, the finding that the ubiquitin ligase function of the
BRCA1: BARD1 is not required for HDR or tumor suppres-
sion in the mouse raises the additional question of why missense
mutations of BRCA1 that disrupt the BRCA1: BARD1 inter-
action (e.g., Cys61Gly) lead to cancer in humans and in mice
(Drost et al., 2011). These considerations would suggest that the
BRCA1: BARD1 interaction may have another ubiquitin ligase-
independent function that is essential for tumor suppression.
Interestingly, BARD1 is itself a tumor suppressor, mutations of
which have been linked to breast, ovarian, and endometrial can-
cers (Ghimenti et al., 2002; Sauer and Andrulis, 2005). However,
curiously, some of the cancer-associated mutants of BARD1 do
not alter the function of BARD1 in HDR (Laufer et al., 2007).
ROLE OF p53 IN BRCA1-DEPENDENT TUMORIGENESIS
As noted above, BRCA1 can interact directly with p53 and stimu-
late its transcriptional activity. Interestingly, in studies of human
BRCA1-related cancers, the incidence of p53 mutations (over
80%) is considerably higher than in sporadic breast cancers (25%)
(Phillips et al., 1999; Holstege et al., 2009). Studies of Brca1
knockout mice revealed early embryonic lethality, usually by day
7.5 (Hakem et al., 1996). The Brca1–/– phenotype was character-
ized by widespread defects in cell proliferation due, in part, to p53
activation. This phenotype was partially reversed by a p53 or p21
deficiency, resulting in embryonic death at later times (Hakem
et al., 1997). It was suggested that p53 was activated due to chro-
mosomal abnormalities created by Brca1 deficiency, causing p53
activation and p21 expression, resulting in cell cycle arrest or
senescence. By the same reasoning, it appears that a p53 muta-
tion is required for BRCA1-related breast cancer development
because otherwise, chromosoml aberrations due to BRCA1 defi-
ciency would activate p53, leading to cell cycle arrest, apoptosis,
and/or senescence of the tumor cells.
In a recent study, it was found that p53 mediates the nuclear
export of wild-type BRCA1 via a BRCA1: p53 protein interaction
and possibly, in part, by disrupting the BRCA1: BARD1 inter-
action (Jiang et al., 2011). It was suggested that this mechanism
could increase cellular sensitivity to DNA damaging agents such
as IR and that loss of p53 function could impair the nuclear export
of BRCA1 in sporadic breast cancers with functional BRCA1,
resulting in greater resistance to DNA damaging agents. Thus, the
functional interaction of BRCA1 and p53 is quite complex and
may influence the molecular pathogenesis of breast cancer, the
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DDRof tumor cells, and their sensitivity to DNAdamaging agents
including chemotherapy drugs and IR.
BRCA1 AND TELOMERES
Telomeres, the ends of chromosomes that contain varying lengths
of hexameric DNA repeats (TTAGGG in mammalian cells) are
of interest in the context of DNA repair for several reasons: (1)
if chromosome ends were recognized as DSBs, it would lead
to genomic instability due to end joining and translocations;
(2) conversely, telomerase is recruited to internal DSBs, where
it could potentially generate a telomere, with disastrous conse-
quences; (3) DNA damage can cause telomere shortening; and (4)
telomere shortening can lead to chromosomal instability and can-
cer development (Günes and Rudolph, 2013; Ribeyre and Shore,
2013). Moreover, tumor cells that do not express telomerase,
the enzyme complex that adds TTAGGG to telomeres, utilize
alternative lengthening of telomeres (ALT), a method of telom-
ere maintenance that involves DNA recombination and utilizes
some of the same DNA repair proteins involved in repairing DSBs
(Nandakumar and Cech, 2013). To start out, telomeres are pro-
tected from being recognized as DSBs, in part, by a complex of
six intrinsic telomeric proteins known collectively as “shelterin”
(TRF1, TRF2, TIN2, TPP1, POT1, andRAP1). Three of these pro-
teins directly bind telomeric DNA (TRF1, TRF2, and POT1); and
the other three proteins (TIN2, TPP1, and RAP1) do not directly
contact DNA but serve to interconnect the three DNA-binding
proteins. The shelterin proteins contribute to the formation of
the telomere loop (t-loop) at the end of the chromosome and
inhibit the activity of ATM and ATR (Raffaella Diotti and Loayza,
2011). In particular, TRF2 and POT1 have been implicated in the
inhibition of ATM and ATR, respectively. Other proteins can bind
transiently to shelterin to alter telomere function.
One group of proteins that bind to shelterin is the MRN com-
plex. In this context, the same MRN complex which initiates the
repair of DSBs, when recruited to the telomere by TRF2 has been
implicated in regulation of telomere length and the telomeric
overhang (Lamarche et al., 2010) (Figure 5A). MRN as well as the
nuclease Apollo have been implicated in generation of the telom-
eric overhang (a 3′ G-rich single-stranded telomeric extension),
which functions in maintaining telomere stability. However, far
less is known about how telomeric MRN functions than how
MRN functions in the sensing and repair of DSBs. As in the case of
the response to DSBs, ATM is required for MRN signaling in the
context of a dysfunctional uncapped telomere (Lamarche et al.,
2010). In this setting a signaling cascade similar to that induced
by DSBs is activated and can result in cell cycle arrest, senescence,
or apoptosis.
In addition to MRN, several studies implicate BRCA1 as a
regulator of telomere length and stability. In the first study, over-
expression of BRCA1 was found to inhibit telomerase enzymatic
activity by transcriptionally repressing expression of the telom-
erase catalytic subunit (telomerase reverse transcriptase, TERT)
(Xiong et al., 2003). The mechanism of repression appears to
be by inhibiting the ability of the c-Myc oncoprotein to stimu-
late TERT expression through the c-Myc E-box within the TERT
proximal promoter. As a consequence of telomerase inhibition,
FIGURE 5 | Model for role of BRCA1 in telomere maintenance. (A)
Shows a linear representation of a normal functional telomere. For
simplicity, not all of the telomere-associated proteins are shown. BRCA1 is
recruited to the telomere by RAD50, a component of the MRN complex,
which is also present at the telomere. When BRCA1 is over-expressed,
more BRCA1 is present at the telomere. BRCA1 causes overall telomere
shortening, but the 3′ G-strand overhang is lengthened, as illustrated in
(B). (C) Shows a critically short and dysfunctional telomere with little or no
3′ G-strand overhang in cells with no functional BRCA1. A DDR is activated
with resultant chromosomal aberrations due to end-end fusions and
translocations (a dicentric chromosome is illustrated). The G-strand
overhang is represented by a thick black line. The thick red lines represent
double-stranded telomeric DNA, while the sub-telomeric DNA is shown as
blue lines.
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over-expression of wild-type BRCA1 but not a cancer-associated
mutant (Cys61Gly) caused telomere shortening in several tumor
cell lines (Figure 5B). Interestingly, despite causing shortening of
telomeres to very small sizes (well under 2.0 kb), BRCA1 did not
cause inhibition of cellular proliferation, cell cycle arrest, senes-
cence, or apoptosis (Xiong et al., 2003). Surprisingly, significant
telomere shortening due to BRCA1 occurred very rapidly (within
2–3 cell doublings), far too fast to be attributable to inhibition
of telomerase activity. These findings suggest that BRCA1 causes
telomere erosion (degradation) but somehow protects against
telomeric dysfunction.
In a second study, it was found that BRCA1 knockdown
resulted in increased telomerase activity and significant telomere
lengthening in tumor cells (Ballal et al., 2009). Based on telom-
eric chromatin immunoprecipitation (telomeric ChIP) assays, the
presence of BRCA1 on telomeres was documented. BRCA1 was
also found to interact and colocalize with shelterin proteins TRF1
and TRF2, in DNA-dependent manner. In further studies, it was
found that BRCA1 was recruited to the telomere by RAD50, a
component of the MRN complex. Finally, it was found that, like
MRN, BRCA1 regulates the length of the 3′ G-rich overhang. Thus
over-expression of BRCA1 caused lengthening and knockdown
of BRCA1 or RAD50 caused a similar degree of shortening of
the 3′ overhang (Figure 5B). These findings suggest that BRCA1
can regulate both telomere length and telomere stability and
may mediate some of the effects of the MRN complex on the
telomere (e.g., overhang length). These findings are consistent
with the observation that cells with no functional BRCA1 exhibit
evidence of telomere dysfunction and loss of the capping func-
tion, evidenced by very short telomeres and the appearance of
chromosomal abnormalities of the type expected from telomere
dysfunctions (e.g., dicentric chromosomes due to end-end fusion)
(Al-Wahiby and Slijepcevic, 2005; McPherson et al., 2006; Wang
et al., 2007b) (Figure 5C). In another study, knockdownofBRCA1
in amammary epithelial cell line caused chromosomal aberrations
consistent with telomere dysfunction (e.g., anaphase bridges). In
addition to BRCA1 and MRN, defects of other DDR-associated
proteins (Ku, DNA-PKcs, and RAD51D) have been linked to the
loss of the telomeric capping function (Cabuy et al., 2008).
Finally, in understanding the relationship between telomeres
and the DDR, it was mentioned above that telomerase is recruited
to DSBs, where under some conditions it can synthesize telom-
eres at the broken ends of DNA (Ribeyre and Shore, 2013). The
discovery of telomeric DNA sequences within the interiors of
chromosomes interstitial telomeric sequences (ITS) of rodents
and primates has been interpreted to mean that at some time dur-
ing evolution telomerase was utilized to repair DSBs (Slijepcevic,
2006). Based on mutational analysis, several studies have demon-
strated the existence of active mechanisms in yeast to prevent the
synthesis of telomeres by the enzyme telomerase at DNA ends
of DSBs (Nergadze et al., 2007; Makovets and Blackburn, 2009;
Zhang and Durocher, 2010). For example, Mec1 (the ortholog of
ATR in yeast) both recognizes DNA ends and inhibits telomerase
at DSBs, a mechanism for the preservation of genomic integrity.
Two such mechanisms involve Mec1-dependent phosphorylation
of Pif1 (a telomerase inhibitor) and Cdc13 (a telomere capping
protein) (Makovets and Blackburn, 2009; Zhang and Durocher,
2010). Genetic analysis in Drosophila identified ATR-interacting
protein (ATRIP) as a factor involved in preventing the forma-
tion of telomeres at the sites of DSBs (Beaucher et al., 2012).
In mammalian cells, ATR: ATRIP complexes are recruited to
ssDNA coated with RPA and are activated by a complex mech-
anism that is not fully understood (Liu et al., 2011). In this
context, ATR: ATRIP complexes have been found to activate
a CHK1-dependent checkpoint mechanism during S-phase in
response to stalled replication forks (Nam and Cortez, 2011).
OTHER DNA DAMAGE-RELATED FUNCTIONS OF BRCA1
While the best studied DNAdamage-related function of BRCA1 is
its role in the repair of DSBs, roles for BRCA1 in other DNA repair
processes have been reported. Thus, BRCA1 has been reporter to
up-regulate the activity of the base excision repair (BER) pathway
through a transcriptional mechanism that involves stimulation of
the expression of several key BER enzymes (OGG1. NTH1, and
REF1/APE1) (Saha et al., 2010a,b). BER is the major pathway for
the repair of oxidized DNA and is normally an error-free pro-
cess. Failure to repair different types of oxidized DNA lesions can
result in cytotoxicity or mutagenesis, which can ultimately lead to
cancer. The mechanism for up-regulation of BER enzyme expres-
sion was identified as stimulation of the activity of the OCT1.
Previously, it was shown that BRCA1, like ATM, mediates a
cytoprotective antioxidant response, characterized by stimulation
of the activity of the antioxidant response transcription factor
NFE2L2 (NRF2) (Bae et al., 2004). Further studies have revealed
that BRCA1, in collaboration with REF1, down-regulates intracel-
lular levels of reactive oxygen species (ROS), oxidized DNA, and
nitrated proteins (Saha et al., 2009). However, the contribution of
these functions of BRCA1 to tumor suppression is unknown.
The Fanconi anemia network consists of a group of proteins
involved in the repair of DNA interstrand cross-links (ICLs),
mutations of which lead to Fanconi anemic, a genetic disor-
der characterized by short stature, chromosomal instability, bone
marrow failure, and increased sensitivity to agents that cause
cross-linking of DNA. The accurate repair of ICLs involves, in
part, HDR as well as the nucleotide excision repair (NER) path-
way. Several studies suggest that BRCA1 participates in the repair
of ICLs. These studies suggest two distinct roles for BRCA1 in
ICL repair, one involving its function in HDR and the other inde-
pendent of HDR (Zhou et al., 2005; Cheng et al., 2006; Bunting
et al., 2012). However, the precise molecular functions of BRCA1
in the repair of ICLs are unclear. Conversely, as described above,
several components within the Fanconi anemia network, interact
with BRCA1 (directly or indirectly) and participate in BRCA1-
dependent DNA repair of DSBs, including FANCJ (=BACH1),
FANCN (=PALB2), and FANCD1 (BRCA2).
In addition to ATM, BRCA1 is also phosphorylated at several
sites by ATR in response to ultraviolet (UV) radiation (Tibbetts
et al., 2000; Gatei et al., 2001). These findings suggest a role
for BRCA1 in the repair of UV damage, which is mediated, in
part, by the NER pathway. In a recent study, it was reported that
BRCA1 participates in the response to UV damage in a manner
that is independent of the NER pathway (Pathania et al., 2011).
Here it was found that following UV damage, BRCA1 is recruited
through its BRCT domains to stalled replication forks, where
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it participates in several processes including excision of photo-
products and recruitment of components of the replication factor
C (RFC) complex, with subsequent checkpoint activation and
post-replicative DNA repair. Unlike BRCA1 recruitment to IRIF
(which is delayed formore than 1 h), BRCA1 is recruited relatively
rapidly (15min) to sites of UV damage, primarily in S-phase cells
(Pathania et al., 2011; Zhang et al., 2013). In one study, it was
reported that BRG1, a component of the SWI/SNF chromatin
remodeling complex, is required for BRCA1 recruitment to UV
damage sites and that BRG1 modulates BRCA1 function in repair
of UV damage by regulating the activation of ATR and ATM.
Several other studies suggest roles for BRCA1 in the repair of UV
damage (Navaraj et al., 2005; Marteijn et al., 2009) and it has
been proposed that BRCA1 transcriptionally up-regulates genes
involved in NER (Hartman and Ford, 2002).
BRCA1 AND PARP
Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme in
the BER pathway that participates in the repair of single-strand
breaks (SSBs) of DNA. Using a “synthetic lethal” screen, it was
found that inhibition of PARP activity causes chromosomal insta-
bility and apoptosis in BRCA1 or BRCA2-mutant cells but not
in BRCA1/BRCA2-competent cells (Farmer et al., 2005). It was
hypothesized that inhibition of PARP causes the accumulation of
unrepaired SSBs that are then converted DSBs that would nor-
mally be repaired by HDR. This observation has led to clinical tri-
als of small molecule PARP inhibitors (which had been originally
developed as chemosensitizers) as a treatment for tumors aris-
ing in BRCA1 and BRCA2mutation carriers (Lord and Ashworth,
2008). In a phase I trial of the PARP inhibitor olaparib (for-
merly AZD2281), significant responses were observed only in
BRCA1-mutant andBRCA2-mutant cancers, with no responses in
tumors wild-type for BRCA (Fong et al., 2009). In another phase
I trial, 40% of patients with ovarian cancers due to germ-line
BRCA1/2 mutations achieved complete or partial responses with
olaparib, with the response rates higher in cis-platinum sensitive
tumors than in cis-platinum resistant tumors (Fong et al., 2010).
Currently, there are eight PARP inhibitors under clinical investi-
gation (with more under development) either as monotherapy, in
combination with chemotherapy and radiotherapy, or in combi-
nation with other specifically targeted agents, for various types of
malignancies (Papeo et al., 2013).
It shouldbenoted that althoughPARP inhibitors still hold great
promise in cancer therapy, de novo resistance or the development
of resistance after an initial response has become problematic
(reviewed in Montoni et al., 2013). For example, in a recent phase
II trial, none of 26 patients with advanced triple negative breast
cancer (tumors that lack estrogen and progesterone receptor
expression and do not exhibit amplification of the HER2/Neu
oncogene) had objective responses to the PARP inhibitor ola-
parib (Gelmon et al., 2011). In contrast a response rate of 41%
was observed in ovarian cancer patients who carry BRCA1 or
BRCA2 mutations (Gelmon et al., 2011). One very interest-
ing study of tumor tissue derived from patients with BRCA2
mutations that had initially responded to olaparib but subse-
quently developed resistance revealed secondary mutations in
the resistant tumors that restored BRCA2 function (Barber et al.,
2013). In a mouse model with a knock-in cancer-associated Brca1
mutation-Cys61Gly), the tumors rapidly developed resistance to
both olaparib and cis-platinum but retained the Brca1 mutation.
CONCLUSIONS AND PERSPECTIVES
Breast and ovarian cancer susceptibility gene 1 is a tumor sup-
pressor gene, inherited mutations of which confer a significantly
increased risk breast and ovarian cancers. BRCA1 functions in
the error-free repair of DSBs of DNA by HDR (also known as
homologous recombination). This function appears to be critical
for its tumor suppressor activity. BRCA1 may also function in a
subtype of non-homologous end joining that is more accurate
than classical error-prone NHEJ, although the role of BRCA1 in
NHEJ is not settled. BRCA1 participates in a number of DNA
damage-activated cell cycle checkpoints (e.g., intra-S and G2/M
checkpoints) and in the response to stalled replication forks (e.g.,
those caused by DNA cross-linking agents). BRCA1 in complex
with BARD1 exerts an E3 ubiquitin ligase activity that was once
thought to be essential for tumor suppression, but this view
was contradicted by a recent study of a transgenic mouse model
homozygous for an engineered mutant Brca1 gene that is defec-
tive for ubiquitin ligase activity but retains the ability to mediate
HDR, since these mice did not develop cancer.
Since BRCA1 expression is widespread, the function of BRCA1
in mediating HDR and other DNA repair processes does not
by itself explain the predilection of BRCA1-mutation carriers
to develop such a limited range of tumor types, mostly breast
and ovarian cancers. It is well-established that breast cancer is an
estrogen-driven tumor type. Thus, the ability of BRCA1 to inhibit
estrogen receptor activity (described above) could contribute to
breast cancer suppression. Here, the idea is that during tumor
development,mammaryepithelial cells that exhibit genomic insta-
bility are stimulated to proliferate excessively because they lack a
major mechanism that limits estrogen-stimulated proliferation.
This hypothesis is consistentwith findings suggesting thatBRCA1-
related tumorigenesis is hormonally responsive, at least in the early
stages. It is expected that BRCA1 also mediates an ovary-specific
function that could explain why the ovary is a preferred site for
cancer development in women who carry BRCA1 mutations.
It was also proposed that BRCA1 functions, including tumor
suppression, can be explained by the ability of BRCA1 to ubiq-
uitinate the histone H2A within satellite DNA, thus maintaining
heterochromatin in a transcriptionally silenced state. Moreover,
a clinical-epidemiologic study suggests that mutations mapping
to the C-terminal region of BRCA1, which would be predicted
to disrupt BRCA1 function in HDR, do not abrogate the abil-
ity of BRCA1 to suppress ovarian cancer. Thus the mechanisms
by which BRCA1 suppresses breast and ovarian cancer develop-
ment may differ. It is worthwhile to note that while mouse models
of Brca1-dependent mammary tumorigenesis yield tumors with
many of the characteristics of the human cancers, these models do
not fully mimic the human situation. In addition to the obvious
differences between mice and humans, BRCA1-related tumorige-
nesis in mouse and humans differ in other characteristics. Thus,
in mice, a homozygous Brca1-mutation is targeted to the mam-
mary gland or other organs, often along with a heterozygous or
homozygous deletion of p53. On the other hand, humans inherit
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one mutant BRCA1 allele, with the other allele being wild-type.
And since the mutation is in the germ-line, all somatic cells are
heterozygous for BRCA1. Thus, the pathway for BRCA1-related
tumorigenesis may not be the same in humans and mice.
We have reviewed evidence that BRCA1 serves other DNA
damage-related functions, including the regulation of telomere
length and stability. Consistent with other DDRproteins that have
complex roles in telomere biology (e.g., MRN, ATM, DNA-PK,
and others), BRCA1 exerts multiple telomere-related functions.
Thus, BRCA1 inhibits telomerase activity and causes telomere
shortening, while at the same time preserving telomere stability
by increasing the length of the G-strand overhang. As a result,
extremely short telomeres in BRCA1 over-expressing tumor cells
did not trigger senescence, apoptosis, or cell cycle arrest. Although
the telomerase activity is reduced in BRCA1 over-expressing cells,
it apparently remains sufficient to maintain the length of the
shortened telomeres and synthesize the 3′ G-strand overhang.
The mechanism by which BRCA1 causes telomere shortening
remains to be determined, since the rate of shortening was too
rapid to be due to the loss of telomerase activity alone. The com-
plete absence of functional BRCA1 creates telomere dysfunction,
evidenced by the appearance of chromosomal aberrations of the
type due to critical telomere shortening. However, assuming that
BRCA1 functions similarly in non-tumor cell types, the ability of
BRCA1 to inhibit telomerase activity and cause telomere short-
ening are consistent with a tumor suppressor function. To what
extent these activities actually contribute to the tumor suppressor
activity of BRCA1 is unclear at present.
Finally, while much progress has been made in understand-
ing how BRCA1 is recruited to IRIF and its function during the
DDR, its precise molecular functions in HDR and other DNA
repair activities (e.g., NEHJ and ICL cross-link repair) remain to
be determined. Furthermore, in understanding the role of HDR
in BRCA1-mediated tumor suppression, it should be realized that
mutations that disrupt this function are likely to disrupt many
other functions of BRCA1; and at present, it is unclear which
of these other functions contribute to tumor suppression and to
what extent.
REFERENCES
Aglipay, J. A., Martin, S. A., Tawara,
H., Lee, S. W., and Ouchi, T.
(2006). ATM activation by ion-
izing radiation requires BRCA1-
associated BAAT1. J. Biol. Chem.
281, 9710–9718.
Al-Wahiby, S., and Slijepcevic, P.
(2005). Chromosomal aberrations
involving telomeres in BRCA1
deficient human and mouse cell
lines. Cytogenet. Genome Res. 109,
491–496.
Bae, I., Fan, S., Meng, Q., Rih, J.
K., Kim, H. J., Kang, H. J., et al.
(2004). BRCA1 induces antioxidant
gene expression and resistance to
oxidative stress. Cancer Res. 64,
7893–7909.
Bae, I., Rih, J. K., Kim, H. J., Kang,
H. J., Haddad, B., Kirilyuk, A.,
et al. (2005). BRCA1 regulates gene
expression for orderly mitotic pro-
gression. Cell Cycle 4, 1641–1666.
Baer, R., and Ludwig, T. (2002). The
BRCA1/BARD1 heterodimer, a
tumor suppressor complex with
ubiquitin E3 ligase activity. Curr.
Opin. Genet. Dev. 12, 86–91.
Bakkenist, C. J., and Kastan, M. B.
(2003). DNA damage activates ATM
through intermolecular autophos-
phorylation and dimer dissociation.
Nature 421, 499–506.
Baldeyron, C., Jacquemin, E., Smith,
J., Jacquemont, C., De Oliveira,
I., Gad, S., et al. (2002). A sin-
gle mutated BRCA1 allele leads to
impaired fidelity of double strand
break end-joining. Oncogene 21,
1401–1410.
Ballal, R. D., Saha, T., Fan, S., Haddad,
B. R., and Rosen, E. M. (2009).
BRCA1 localization to the telomere
and its loss from the telomere in
response to DNA damage. J. Biol.
Chem. 284, 36083–36098.
Barber, L. J., Sandhu, S., Chen, L.,
Campbell, J., Kozarewa, I., Fenwick,
K., et al. (2013). Secondary muta-
tions in BRCA2 associated with clin-
ical resistance to a PARP inhibitor.
J. Pathol. 229, 422–429.
Bau, D. T., Fu, Y. P., Chen, S. T.,
Cheng, T. C., Yu, J. C., Wu, P. E.,
et al. (2004). Breast cancer risk and
the DNA double-strand break end-
joining capacity of nonhomologous
end-joining genes are affected by
BRCA1. Cancer Res. 64, 5013–5019.
Beaucher, M., Zheng, X. F., Amariei,
F., and Rong, Y. S. (2012). Multiple
pathways suppress telomere
addition to DNA breaks in the
Drosophila germline. Genetics 191,
407–417.
Bork, P., Hofmann, K., Bucher, P.,
Neuwald, A. F., Altschul, S. F., and
Koonin, E. V. (1997). A superfam-
ily of conserved domains in DNA
damage-responsive cell cycle check-
point proteins. FASEB J. 11, 68–76.
Brzovic, P. S., Rajagopal, P., Hoyt, D.
W., King, M. C., and Klevit, R.
E. (2001). Structure of a BRCA1-
BARD1 heterodimeric RING-RING
complex. Nat. Struct. Biol. 8,
833–837.
Buis, J., Stoneham, T., Spehalski, E.,
and Ferguson, D. O. (2012). Mre11
regulates CtIP-dependent double-
strand break repair by interaction
with CDK2. Nat. Struct. Mol. Biol.
19, 246–252.
Buisson, R., and Masson, J. Y. (2012).
PALB2 self-interaction controls
homologous recombination.
Nucleic Acids Res. 40, 10312–10323.
Bunting, S. F., Callén, E., Kozak, M.
L., Kim, J. M., Wong, N., López-
Contreras, A. J., et al. (2012).
BRCA1 functions independently
of homologous recombination in
DNA interstrand crosslink repair.
Mol. Cell 46, 125–135.
Burma, S., Chen, B. P., Murphy, M.,
Kurimasa, A., and Chen, D. J.
(2001). ATM phosphorylates his-
tone 2001 H2AX in response to
DNA doublestrand breaks. J. Biol.
Chem. 276, 42462–42467.
Cabuy, E., Newton, C., and Slijepcevic,
P. (2008). BRCA1 knock-down
causes telomere dysfunction
in mammary epithelial cells.
Cytogenet. Genome Res. 122,
336–342.
Campbell, S. J., Edwards, R. A., Leung,
C. C., Neculai, D., Hodge, C. D.,
Dhe-Paganon, S., et al. (2012).
Molecular insights into the function
of RING finger (RNF)-containing
proteins hRNF8 and hRNF168 in
Ubc13/Mms2-dependent ubiq-
uitylation. J. Biol. Chem. 287,
23900–23010.
Cantor, S., Drapkin, R., Zhang, F.,
Lin, Y., Han, J., Pamidi, S., et al.
(2004). The BRCA1-associated pro-
tein BACH1 is a DNA helicase tar-
geted by clinically relevant inactivat-
ing mutations. Proc. Natl. Acad. Sci.
U.S.A.101, 2357–2362.
Cheng, W. H., Kusumoto, R., Opresko,
P. L., Sui, X., Huang, S., Nicolette,
M. L., et al. (2006). Collaboration
of Werner syndrome protein
and BRCA1 in cellular responses
to DNA interstrand cross-links.
Nucleic Acids Res. 34, 2751–2760.
Costes, S. V., Chiolo, I., Pluth, J. M.,
Barcellos-Hoff, M. H., and Jakob,
B. (2010). Spatiotemporal char-
acterization of ionizing radiation
induced DNA damage foci and
their relation to chromatin
organization. Mutat. Res. 704,
78–87.
Deming, P. B., Cistulli, C. A., Zhao,
H., Graves, P. R., Piwnica-Worms,
H., Paules, R. S., et al. (2001).
The human decatenation check-
point. Proc. Natl. Acad. Sci. U.S.A.
98, 12044–12049.
Dever, S. M., White, E. R., Hartman,
M. C., and Valerie, K. (2012).
BRCA1-directed, enhanced and
aberrant homologous recombi-
nation: mechanism and potential
treatment strategies. Cell Cycle 11,
687–694.
Ditch, S., and Paull, T. T. (2012). The
ATM protein kinase and cellular
redox signaling: beyond the DNA
damage response. Trends Biochem.
Sci. 37, 15–22.
Drost, R., Bouwman, P., Rottenberg, S.,
Boon, U., Schut, E., Klarenbeek, S.,
et al. (2011). BRCA1 RING func-
tion is essential for tumor sup-
pression but dispensable for ther-
apy resistance. Cancer Cell 20,
797–809.
Durant, S. T., and Nickoloff, J. A.
(2005). The roles of BRCA1 and
BRCA2 and associated proteins in
the maintenance of genomic stabil-
ity. Cell Cycle 9, 1216–1222.
Escribano-Díaz, C., Orthwein, A.,
Fradet-Turcotte, A., Xing, M.,
Young, J. T., Tkác, J., et al. (2013).
A cell cycle-dependent regulatory
circuit composed of 53BP1-RIF1
and BRCA1-CtIP controls DNA
repair pathway choice. Mol. Cell 49,
872–883.
www.frontiersin.org June 2013 | Volume 4 | Article 85 | 11
Rosen BRCA1 in DNA damage response
Esteller, M., Silva, J. M., Dominguez,
G., Bonilla, F., Matias-Guiu, X.,
Lerma, E., et al. (2000). Promoter
hypermethylation and BRCA1 inac-
tivation in sporadic breast and ovar-
ian tumors. J. Natl. Cancer Inst. 92,
564–569.
Fabbro, M., Savage, K., Hobson,
K., Deans, A. J., Powell, S.
N., McArthur, G. A., et al.
(2004). BRCA1-BARD1 complexes
are required for p53Ser-15 phos-
phorylation and a G1/S arrest fol-
lowing ionizing radiation-induced
DNA damage. J. Biol. Chem. 279,
31251–31258.
Farmer, H., McCabe, N., Lord, C.
J., Tutt, A. N., Johnson, D. A.,
Richardson, T. B., et al. (2005).
Targeting the DNA repair defect in
BRCA mutant cells as a therapeutic
strategy. Nature 434, 917–921.
Feng, L., Fong, K. W., Wang, J.,
Wang, W., and Chen, J. (2013).
RIF1 counteracts BRCA1-
mediated end resection during
DNA repair. J. Biol. Chem. 288,
11135–11143.
Fong, P. C., Boss, D. S., Yap, T. A.,
Tutt, A., Wu, P., Mergui-Roelvink,
M., et al. (2009). Inhibition of
poly(ADP-ribose) polymerase in
tumors from BRCA mutation car-
riers. N. Engl. J. Med. 361, 123–134.
Fong, P. C., Yap, T. A., Boss, D. S.,
Carden, C. P., Mergui-Roelvink,
M., Gourley, C., et al. (2010).
Poly(ADP)-ribose polymerase
inhibition: frequent durable
responses in BRCA carrier ovarian
cancer correlating with platinum-
free interval. J. Clin. Oncol. 28,
2512–2519.
Gatei, M., Zhou, B. B., Hobson, K.,
Scott, S., Young, D., and Khanna,
K. K. (2001). Ataxia telangiectasia
mutated (ATM) kinase and ATM
and Rad3 related kinase mediate
phosphorylation of Brca1 at dis-
tinct and overlapping sites. In vivo
assessment using phospho-specific
antibodies. J. Biol. Chem. 276,
17276–17280.
Gayther, S. A., Warren, W., Mazoyer,
S., Russell, P. A., Harrington, P. A.,
Chiano, M., et al. (1995). Germline
mutations of the BRCA1 gene in
breast and ovarian cancer families
provide evidence for a genotype-
phenotype correlation. Nat. Genet.
11, 428–433.
Gelmon, K. A., Tischkowitz, M.,
Mackay, H., Swenerton, K.,
Robidoux, A., Tonkin, K., et al.
(2011). Olaparib in patients with
recurrent high-grade serous or
poorly differentiated ovarian car-
cinoma or triple-negative breast
cancer: a phase 2, multicentre,
open-label, non-randomised study.
Lancet Oncol. 12, 852–861.
Ghimenti, C., Sensi, E., Presciuttini,
S., Brunetti, I. M., Conte, P.,
Bevilacqua, G., et al. (2002).
Germline mutations of the BRCA1-
associated ring domain (BARD1)
gene in breast and breast/ovarian
families negative for BRCA1
and BRCA2 alterations. Genes
Chromosomes Cancer 33, 235–242.
Gong, Z., Kim, J. E., Leung, C. C.,
Glover, J. N., and Chen, J. (2010).
BACH1/FANCJ acts with TopBP1
and participates early in DNA repli-
cation checkpoint control. Mol. Cell
37, 438–446.
Goodarzi, A. A., Jonnalagadda, J. C.,
Douglas, P., Young, D., Ye, R.,
Moorhead, G. B., et al. (2004).
Autophosphorylation of ataxia-
telangiectasia mutated is regulated
by protein phosphatase 2A. EMBO
J. 23, 4451–4461.
Gudmundsdottir, K., and Ashworth, A.
(2006). The roles of BRCA1 and
BRCA2 and associated proteins in
the maintenance of genomic stabil-
ity. Oncogene 25, 5864–5874.
Günes, C., and Rudolph, K. L. (2013).
The role of telomeres in stem cells
and cancer. Cell 152, 390–393.
Guo, Z., Kozlov, S., Lavin, M. F., Person,
M. D., and Paull, T. T. (2010).
ATM activation by oxidative stress.
Science 330, 517–521.
Hakem, R., de la Pompa, J. L., Elia,
A., Potter, J., and Mak, T. W.
(1997). Partial rescue of Brca1 (5–6)
early embryonic lethality by p53 or
p21 null mutation. Nat. Genet. 16,
298–302.
Hakem, R., de la Pompa, J. L., Sirard,
C., Mo, R., Woo, M., Hakem, A.,
et al. (1996). The tumor suppressor
gene Brca1 is required for embry-
onic cellular proliferation in the
mouse. Cell 85, 1009–1023.
Harris, J. L., and Khanna, K. K. (2011).
BRCA1 A-complex fine tunes repair
functions of BRCA1. Aging (Albany
NY) 3, 461–463.
Hartman, A. R., and Ford, J. M. (2002).
BRCA1 induces DNA damage
recognition factors and enhances
nucleotide excision repair. Nat.
Genet. 32, 180–184.
Hashizume, R., Fukuda, M., Maeda, I.,
Nishikawa,H., Oyake, D., Yabuki, Y.,
et al. (2001). The RINGheterodimer
BRCA1-BARD1 is a ubiquitin ligase
inactivated by a breast cancer-
derived mutation. J. Biol. Chem.
276, 14537–14540.
Holstege, H., Joosse, S. A., van Oost-
rom, C. T., Nederlof, P. M., de Vries,
A., and Jonkers, J. (2009). High
incidence of protein-truncating
TP53 mutations in BRCA1-related
breast cancer. Cancer Res. 69,
3625–3633.
Jiang, J., Yang, E. S., Jiang, G., Now-
sheen, S., Wang, H., Wang, T.,
et al. (2011). p53-dependent BRCA1
nuclear export controls cellular sus-
ceptibility to DNA damage. Cancer
Res. 71, 5546–5557.
Jin, Y., Xu, X. L., Yang, M. C., Wei,
F., Ayi, T. C., Bowcock, A. M.,
et al. (1997). Cell cycle-dependent
colocalization of BARD1 and
BRCA1 proteins in discrete nuclear
domains. Proc. Natl. Acad. Sci.
U.S.A. 94, 12075–12080.
Kastan, M. B., and Lim, D. S. (2000).
The many substrates and functions
of ATM. Nat. Rev. Mol. Cell Biol. 1,
179–186.
Kim, H., Huang, J., and Chen, J.
(2007a). CCDC98 is a BRCA1-
BRCT domain-binding protein
involved in the DNA damage
response. Nat. Struct. Mol. Biol. 14,
710–715.
Kim, H., Chen, J., and Yu, X. (2007b).
Ubiquitin-binding protein RAP80
mediates BRCA1-dependent DNA
damage response. Science 316,
1202–1205.
Kleiman, F. E., and Manley, J.
L. (1999). Functional inter-
action of BRCA1-associated
BARD1 with polyadenylation
factor CstF-50. Science 285,
1576–1579.
Kleiman, F. E., and Manley, J. L.
(2001). The BARD1-CstF-50 inter-
action links mRNA 3’ end forma-
tion to DNA damage and tumor
suppression. Cell 104, 743–753.
Kolas, N. K., Chapman, J. R., Nakada,
S., Ylanko, J., Chahwan, R., Sweeney,
F. D., et al. (2007). Orchestration of
the DNA-damage response by the
RNF8 ubiquitin ligase. Science 318,
1637–1640.
Kumaraswamy, E., and Shiekhattar,
R. (2007). Activation of
BRCA1/BRCA2-associated heli-
case BACH1 is required for timely
progression through S phase. Mol.
Cell. Biol. 27, 6733–6741.
Lamarche, B. J., Orazio, N. I., and
Weitzman, M. D. (2010). The MRN
complex in double-strand break
repair and telomere maintenance.
FEBS Lett. 584, 3682–3695.
Laufer, M., Nandula, S. V., Modi,
A. P., Wang, S., Jasin, M., Murty,
V. V., et al. (2007). Structural
requirements for the BARD1
tumor suppressor in chromosomal
stability and homology-directed
DNA repair. J. Biol. Chem. 282,
34325–34333.
Lavin, M. F., and Kozlov, S. (2007).
ATM activation and DNA damage
response. Cell Cycle 6, 931–942.
Lee, J. H., and Paull, T. T. (2005).
ATM activation by DNA double-
strand breaks through the Mre11-
Rad50-Nbs1 complex. Science 308,
551–554.
Lee, M. S., Edwards, R. A., Thede, G. L.,
and Glover, J. N. (2005). Structure
of the BRCT repeat domain of
MDC1 and its specificity for the free
COOH-terminal end of the gamma-
H2AX histone tail. J. Biol. Chem.
280, 32053–32056.
Lieber, M. R. (2010). The mecha-
nism of double-strand DNA break
repair by the nonhomologous DNA
end-joining pathway. Annu. Rev.
Biochem. 79, 181–211.
Liu, S., Shiotani, B., Lahiri, M.,
Maréchal, A., Tse, A., Leung, C. C.,
et al. (2011). ATR autophospho-
rylation as a molecular switch for
checkpoint activation. Mol. Cell 43,
192–202.
Lord, C. J., and Ashworth, A. (2008).
Targeted therapy for cancer using
PARP inhibitors. Curr. Opin.
Pharmacol. 8, 363–369.
Lou, Z., Minter-Dykhouse, K., Franco,
S., Gostissa, M., Rivera, M. A.,
Celeste, A., et al. (2006). MDC1
maintains genomic stability by par-
ticipating in the amplification of
ATM-dependent DNA damage sig-
nals. Mol. Cell 21, 187–200.
Makovets, S., and Blackburn, E. H.
(2009). DNA damage signalling pre-
vents deleterious telomere addition
at DNA breaks. Nat. Cell Biol. 11,
1383–1386.
Manke, I. A., Lowery, D. M., Nguyen,
A., and Yaffe, M. B. (2003). BRCT
repeats as phosphopeptide-binding
modules involved in protein target-
ing. Science 302, 636–639.
Marteijn, J. A., Bekker-Jensen, S., Mai-
land, N., Lans, H., Schwertman,
P., Gourdin, A. M., et al. (2009).
Nucleotide excision repair-induced
H2A ubiquitination is dependent on
MDC1 and RNF8 and reveals a uni-
versal DNA damage response. J. Cell
Biol. 186, 835–847.
Mattiroli, F., Vissers, J. H., van Dijk, W.
J., Ikpa, P., Citterio, E., Vermeulen,
W., et al. (2012). RNF168 ubiqui-
tinates K13-15 on H2A/H2AX to
drive DNA damage signaling. Cell
150, 1182–1195.
McPherson, J. P., Hande, M. P.,
Poonepalli, A., Lemmers, B.,
Zablocki, E., Migon, E., et al.
(2006). A role for Brca1 in chromo-
some end maintenance. Hum. Mol.
Genet. 15, 831–838.
Merajver, S. D., Frank, T. S., Xu,
J., Pham, T. M., Calzone, K. A.,
Bennett-Baker, P., et al. (1995).
Germline BRCA1 mutations and
loss of the wild-type allele in tumors
Frontiers in Genetics | Cancer Genetics June 2013 | Volume 4 | Article 85 | 12
Rosen BRCA1 in DNA damage response
from families with early onset breast
and ovarian cancer. Clin. Cancer
Res. 1, 539–544.
Mérel, P., Prieur, A., Pfeiffer, P., and
Delattre, O. (2002). Absence of
major defects in non-homologous
DNA end joining in human breast
cancer cell lines. Oncogene 21,
5654–5659.
Miki, Y., Swensen, J., Shattuck-Eidens,
D., Futreal, P. A., Harshman, K.,
Tavtigian, S., et al. (1994). A strong
candidate for the breast and ovarian
cancer susceptibility gene BRCA1.
Science 266, 66–71.
Monteiro, A. N., August, A., and
Hanafusa, H. (1996). Evidence for
a transcriptional activation func-
tion of BRCA1 C-terminal region.
Proc. Natl. Acad. Sci. U.S.A. 93,
13595–13599.
Montoni, A., Robu, M., Pouliot, E.,
and Shah, G. M. (2013). Resistance
to PARP-inhibitors in cancer
therapy. Front. Pharmacol. 4:18.
doi:10.3389/fphar.2013.00018
Morris, J. R., Pangon, L., Boutell,
C., Katagiri, T., Keep, N. H., and
Solomon, E. (2006). Genetic analy-
sis of BRCA1 ubiquitin ligase activ-
ity and its relationship to breast can-
cer susceptibility. Hum. Mol. Genet.
15, 599–606.
Moynahan, M. E., Chiu, J. W., Koller,
B. H., and Jasin, M. (1999). Brca1
controls homology-directed DNA
repair. Mol. Cell 4, 511–518.
Moynahan, M. E., Cui, T. Y., and Jasin,
M. (2001). Homology-directed
dna repair, mitomycin-c resis-
tance, and chromosome stability
is restored with correction of a
Brca1 mutation. Cancer Res. 61,
4842–4850.
Moynahan, M. E., and Jasin, M. (2010).
Mitotic homologous recombination
maintains genomic stability and
suppresses tumorigenesis. Nat. Rev.
Mol. Cell Biol. 11, 196–207.
Nam, E. A., and Cortez, D. (2011). ATR
signalling: more than meeting at the
fork. Biochem. J. 436, 527–536.
Nandakumar, J., and Cech, T. R. (2013).
Finding the end: recruitment of
telomerase to telomeres. Nat. Rev.
Mol. Cell Biol. 14, 69–82.
Navaraj, A., Mori, T., and El-Deiry,
W. S. (2005). Cooperation between
BRCA1 and p53 in repair of
cyclobutane pyrimidine dimers.
Cancer Biol. Ther. 4, 1409–1414.
Nergadze, S. G., Santagostino, M. A.,
Salzano, A., Mondello, C., and
Giulotto, E. (2007). Contribution
of telomerase RNA retrotran-
scription to DNA double-strand
break repair during mammalian
genome evolution. Genome Biol.
8, R260.
Papeo, G., Casale, E., Montagnoli,
A., and Cirla, A. (2013). PARP
inhibitors in cancer therapy: an
update. Expert Opin. Ther. Pat. 23,
503–514.
Pathania, S., Nguyen, J., Hill, S. J.,
Scully, R., Adelmant, G. O., Marto, J.
A., et al. (2011). BRCA1 is required
for postreplication repair after UV-
induced DNA damage. Mol. Cell 44,
235–251.
Peng, M., Litman, R., Jin, Z., Fong, G.,
and Cantor, S. B. (2006). BACH1
is a DNA repair protein supporting
BRCA1 damage response. Oncogene
25, 2245–2253.
Phillips, K. A., Nichol, K., Ozcelik, H.,
Knight, J., Done, S. J., Goodwin,
P. J., et al. (1999). Frequency of
p53 mutations in breast carcinomas
from Ashkenazi Jewish carriers of
BRCA1 mutations. J. Natl. Cancer
Inst. 91, 469–473.
Raffaella Diotti, R., and Loayza, D.
(2011). Shelterin complex and asso-
ciated factors at human telomeres.
Nucleus 2, 119–135.
Reid, L. J., Shakya, R., Modi, A. P., Lok-
shin, M., Cheng, J. T., Jasin, M.,
et al. (2008). E3 ligase activity of
BRCA1 is not essential for mam-
malian cell viability or homology-
directed repair of double-strand
DNA breaks. Proc. Natl. Acad. Sci.
U.S.A. 105, 20876–20881.
Ribeyre, C., and Shore, D. (2013).
Regulation of telomere addition
at DNA double-strand breaks.
Chromosoma 122, 159–173.
Rice, J. C., Massey-Brown, K. S., and
Futscher, B. W. (1998). Aberrant
methylation of the BRCA1 CpG
island promoter is associated with
decreased BRCA1 mRNA in spo-
radic breast cancer cells. Oncogene
17, 1807–1812.
Rodríguez, J. A., and Henderson,
B. R. (2000). Identification of a
functional nuclear export sequence
in BRCA1. J. Biol. Chem. 275,
38589–38596.
Rosen, E. M., Fan, S., and Isaacs,
C. (2005). BRCA1 in hormonal
carcinogenesis: basic and clinical
research. Endocr. Relat. Cancer 12,
533–548.
Rosen, E. M., Fan, S., and Ma, Y.
(2006). BRCA1 regulation of
transcription. Cancer Lett. 236,
175–185.
Ruffner, H., Joazeiro, C. A., Hem-
mati, D., Hunter, T., and Verma,
I. M. (2001). Cancer-predisposing
mutations within the RING domain
of BRCA1: loss of ubiquitin pro-
tein ligase activity and protec-
tion from radiation hypersensitiv-
ity. Proc. Natl. Acad. Sci. U.S.A. 98,
5134–5139.
Saha, T., Rih, J. K., and Rosen, E.
M. (2009). BRCA1 down-regulates
cellular levels of reactive oxygen
species. FEBS Lett. 583, 1535–1543.
Saha, T., Rih, J. K., Roy, R., Ballal,
R., and Rosen, E. M. (2010a).
Transcriptional regulation of
the base excision repair pathway
by BRCA1. J. Biol. Chem. 285,
19092–19105.
Saha, T., Smulson, M., and Rosen, E. M.
(2010b). BRCA1 regulation of base
excision repair pathway. Cell Cycle 9,
2471–2472.
Sartori, A. A., Lukas, C., Coates, J.,
Mistrik, M., Fu, S., Bartek, J.,
et al. (2007). Human CtIP pro-
motes DNA end resection. Nature
450, 509–514.
Sauer, M. K., and Andrulis, I. L.
(2005). Identification and charac-
terization of missense alterations
in the BRCA1 associated RING
domain (BARD1) gene in breast and
ovarian cancer. J. Med. Genet. 42,
633–638.
Scully, R., Chen, J., Plug, A., Xiao,
Y., Weaver, D., Feunteun, J., et al.
(1997a). Association of BRCA1 with
Rad51 in mitotic and meiotic cells.
Cell 88, 265–275.
Scully, R., Chen, J., Ochs, R. L., Keegan,
K., Hoekstra, M., Feunteun, J.,
et al. (1997b). Dynamic changes
of BRCA1 subnuclear location
and phosphorylation state are
initiated by DNA damage. Cell 90,
425–435.
Scully, R., Ganesan, S., Vlasakova,
K., Chen, J., Socolovsky, M., and
Livingston, D. M. (1999). Genetic
analysis of BRCA1 function in a
defined tumor cell line. Mol. Cell 4,
1093–1099.
Shakya, R., Reid, L. J., Reczek, C. R.,
Cole, F., Egli, D., Lin, C. S., et al.
(2011). BRCA1 tumor suppression
depends on BRCT phosphoprotein
binding, but not its E3 ligase activ-
ity. Science 334, 525–528.
Shen, S. X., Weaver, Z., Xu, X.,
Li, C., Weinstein, M., Chen, L.,
et al. (1998). A targeted disruption
of the murine Brca1 gene causes
gamma-irradiation hypersensitivity
and genetic instability. Oncogene 17,
3115–3124.
Slijepcevic, P. (2006). The role of DNA
damage response proteins at telom-
eres – an “integrative” model. DNA
Repair (Amst.) 5, 1299–1306.
Sobhian, B., Shao, G., Lilli, D. R.,
Culhane, A. C., Moreau, L. A., Xia,
B., et al. (2007). RAP80 targets
BRCA1 to specific ubiquitin struc-
tures at DNA damage sites. Science
316, 1198–1202.
Spycher, C., Miller, E. S., Townsend, K.,
Pavic, L., Morrice, N. A., Janscak, P.,
et al. (2008). Constitutive phospho-
rylation of MDC1 physically links
the MRE11-RAD50-NBS1 complex
to damaged chromatin. J. Cell Biol.
181, 227–240.
Staff, S., Isola, J., and Tanner, M. (2003).
Haplo-insufficiency of BRCA1 in
sporadic breast cancer. Cancer Res.
63, 4978–4983.
Stark, J. M., Hu, P., Pierce, A. J.,
Moynahan, M. E., Ellis, N., and
Jasin, M. (2002). ATP hydroly-
sis by mammalian RAD51 has a
key role during homology-directed
DNA repair. J. Biol. Chem. 277,
20185–20194.
Stewart, G. S., Wang, B., Bignell, C.
R., Taylor, A. M., and Elledge, S. J.
(2003). MDC1 is a mediator of the
mammalian DNA damage check-
point. Nature 421, 961–966.
Stolz, A., Ertych, N., Kienitz, A.,
Vogel, C., Schneider, V., Fritz, B.,
et al. (2010a). The CHK2-BRCA1
tumour suppressor pathway ensures
chromosomal stability in human
somatic cells. Nat. Cell Biol. 12,
492–499.
Stolz, A., Ertych, N., and Bastians,
H. (2010b). Loss of the tumour-
suppressor genes CHK2 and BRCA1
results in chromosomal instability.
Biochem. Soc. Trans. 38, 1704–1708.
Strauss, C., Halevy, T., Macarov, M.,
Argaman, L., and Goldberg, M.
(2011). MDC1 is ubiquitylated on
its tandem BRCT domain and
directly binds RAP80 in aUBC13-
dependent manner. DNA Repair
(Amst.) 10, 806–814.
Sun, Y., Jiang, X., and Price, B. D.
(2010). Tip60: connecting chro-
matin to DNA damage signaling.
Cell Cycle 9, 930–936.
Sy, S. M., Huen, M. S., and Chen,
J. (2009). PALB2 is an integral
component of the BRCA complex
required for homologous recombi-
nation repair. Proc. Natl. Acad. Sci.
U.S.A. 106, 7155–7160.
Symington, L. S., and Gautier, J. (2011).
Double-strand break end resection
and repair pathway choice. Annu.
Rev. Genet. 45, 247–271.
Taylor, J., Lymboura, M., Pace, P. E.,
A’Hern, R. P., Desai, A. J., Shousha,
S., et al. (1998). An important role
for BRCA1 in breast cancer pro-
gression is indicated by its loss in
a large proportion of nonfamilial
breast cancers. Int. J. Cancer 79,
334–342.
Thompson, D., Easton, D. F., and
Breast Cancer Linkage Consortium.
(2002). Cancer incidence in BRCA1
mutation carriers. J. Natl. Cancer
Inst. 94, 1358–1365.
Tibbetts, R. S., Cortez, D., Brumbaugh,
K. M., Scully, R., Livingston,
www.frontiersin.org June 2013 | Volume 4 | Article 85 | 13
Rosen BRCA1 in DNA damage response
D., Elledge, S. J., et al. (2000).
Functional interactions between
BRCA1 and the checkpoint kinase
ATR during genotoxic stress. Genes
Dev. 14, 2989–3002.
Tirkkonen, M., Johannsson, O.,
Agnarsson, B. A., Olsson, H.,
Ingvarsson, S., Karhu, R., et al.
(1997). Distinct somatic genetic
changes associated with tumor
progression in carriers of BRCA1
and BRCA2 germline mutations.
Cancer Res. 57, 1222–1227.
Tomimatsu, N., Mukherjee, B., Deland,
K., Kurimasa, A., Bolderson, E.,
Khanna, K. K., et al. (2012). Exo1
plays a major role in DNA end
resection in humans and influ-
ences double-strand break repair
and damage signaling decisions.
DNA Repair (Amst.) 11, 441–448.
Wang, B. (2012). BRCA1 tumor sup-
pressor network: focusing on its tail.
Cell Biosci. 2, 6.
Wang, B., Matsuoka, S., Ballif, B. A.,
Zhang, D., Smogorzewska, A., Gygi,
S. P., et al. (2007a). Abraxas and
RAP80 form a BRCA1 protein com-
plex required for the DNA damage
response. Science 316, 1194–1198.
Wang, X., Liu, L., Montagna, C.,





ity, apoptosis, and embryonic
lethality. Cell Death Differ. 14,
924–931.
Wang, H., Wang, M., Wang, H.,
Böcker, W., and Iliakis, G. (2005).
Complex H2AX phosphoryla-
tion patterns by multiple kinases
including ATM and DNA-PK in
human cells exposed to ionizing
radiation and treated with kinase
inhibitors. J. Cell. Physiol. 202,
492–502.
Wang, H., Zeng, Z. C., Bui, T. A.,
DiBiase, S. J., Qin, W., Xia, F.,
et al. (2001). Nonhomologous
end-joining of ionizing radiation-
induced DNA double-stranded
breaks in human tumor cells defi-
cient in BRCA1 or BRCA2. Cancer
Res. 61, 270–277.
Wang, R. H., Yu, H., and Deng, C.
X. (2004). A requirement for
breast-cancer-associated gene 1
(BRCA1) in the spindle checkpoint.
Proc. Natl. Acad. Sci. U.S.A. 101,
17108–17113.
Weaver, Z., Montagna, C., Xu, X.,
Howard, T., Gadina, M., Brodie,
S. G., et al. (2002). Mammary
tumors in mice conditionally
mutant for Brca1 exhibit gross
genomic instability and centro-
some amplification yet display a
recurring distribution of genomic
imbalances that is similar to
human breast cancer. Oncogene 21,
5097–5107.
Westermark, U. K., Reyngold, M.,
Olshen, A. B., Baer, R., Jasin,
M., and Moynahan, M. E. (2003).
BARD1 participates with BRCA1 in
homology-directed repair of chro-
mosome breaks. Mol. Cell. Biol. 23,
7926–7936.
Wilson, C. A., Ramos, L., Villasenor,
M. R., Anders, K. H., Press,
M. F., Clarke, K., et al. (1999).
Localization of human BRCA1 and
its loss in high-grade, non-inherited
breast carcinomas. Nat. Genet. 21,
236–240.
Wooster, R., Bignell, G., Lancaster, J.,
Swift, S., Seal, S., Mangion, J., et al.
(1995). Identification of the breast
cancer susceptibility gene BRCA2.
Nature 378, 789–792.
Wu, L. C., Wang, Z. W., Tsan, J. T.,
Spillman, M. A., Phung, A., Xu, X.
L., et al. (1996). Identification of a
RING protein that can interact in
vivo with the BRCA1 gene product.
Nat. Genet. 14, 430–440.
Wu, W., Koike, A., Takeshita, T., and
Ohta, T. (2008). The ubiquitin E3
ligase activity of BRCA1 and its bio-
logical functions. Cell Div. 3, 1.
Xiong, J., Fan, S., Meng, Q., Schramm,
L., Wang, C., Bouzahza, B., et al.
(2003). BRCA1 inhibition of telom-
erase activity in cultured cells. Mol.
Cell. Biol. 23, 8668–8690.
Xu, B., Kim, S. T., and Kastan, M. B.
(2001). Involvement of Brca1 in S-
phase and G(2)-phase checkpoints
after ionizing irradiation. Mol. Cell.
Biol. 21, 3445–3450.
Xu, B., O’Donnell, A. H., Kim, S. T.,
and Kastan, M. B. (2002). Phospho-
rylation of serine 1387 in Brca1 is
specifically required for the Atm-
mediated S-phase checkpoint after
ionizing irradiation. Cancer Res. 62,
4588–4591.
Xu, X., Weaver, Z., Linke, S. P., Li,
C., Gotay, J., Wang, X. W., et al.
(1999). Centrosome amplifica-
tion and a defective G2-M cell
cycle checkpoint induce genetic
instability in BRCA1 exon 11
isoform-deficient cells. Mol. Cell 3,
389–395.
Yan, J., and Jetten, A. M. (2008).
RAP80 and RNF8, key players in
the recruitment of repair proteins to
DNA damage sites. Cancer Lett. 271,
179–190.
Yarden, R. I., Pardo-Reoyo, S., Sga-
gias, M., Cowan, K. H., and Brody,
L. C. (2002). BRCA1 regulates
the G2/M checkpoint by activating
Chk1 kinase upon DNA damage.
Nat. Genet. 30, 285–289.
Yu, X., Fu, S., Lai, M., Baer, R.,
and Chen, J. (2006). BRCA1
ubiquitinates its phosphorylation-
dependent binding partner CtIP.
Genes Dev. 20, 1721–1726.
Zhang, F., Bick, G., Park, J. Y.,
and Andreassen, P. R. (2012).
MDC1 and RNF8 function in
a pathway that directs 2012
BRCA1-dependent localization of
PALB2 required for homologous
recombination. J. Cell Sci. 125,
6049–6057.
Zhang, F., Fan, Q., Ren, K., and
Andreassen, P. R. (2009). PALB2
functionally connects the breast
cancer susceptibility proteins
BRCA1 and BRCA2. Mol. Cancer
Res. 7, 1110–1118.
Zhang, L., Chen, H., Gong, M., and
Gong, F. (2013). The chromatin
remodeling protein BRG1 mod-
ulates BRCA1 response to UV
irradiation by regulating ATR/ATM
activation. Front. Oncol. 3:7.
doi:10.3389/fonc.2013.00007
Zhang, W., and Durocher, D. (2010).
De novo telomere formation is
suppressed by the Mec1-dependent
inhibition of Cdc13 accumulation
at DNA breaks. Genes Dev. 24,
502–515.
Zhong, Q., Chen, C. F., Chen, P. L., and
Lee, W. H. (2002a). BRCA1 facil-
itates microhomology-mediated
end joining of DNA double
strand breaks. J. Biol. Chem. 277,
28641–22867.
Zhong, Q., Boyer, T. G., Chen, P. L.,
and Lee, W. H. (2002b). Deficient
nonhomologous end-joining activ-
ity in cell-free extracts from Brca1-
null fibroblasts. Cancer Res. 62,
3966–3970.
Zhou, C., Huang, P., and Liu, J. (2005).
The carboxyl-terminal of BRCA1
is required for subnuclear assem-
bly of RAD51 after treatment with
cisplatin but not ionizing radia-
tion in human breast and ovarian
cancer cells. Biochem. Biophys. Res.
Commun. 336, 952–960.
Zhu, Q., Pao, G. M., Huynh, A.M., Suh,
H., Tonnu, N., Nederlof, P. M., et al.
(2011). BRCA1 tumour suppression
occurs via heterochromatin-
mediated silencing. Nature 477,
179–184.
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 09 April 2013; paper pending
published: 19 April 2013; accepted: 25
April 2013; published online: 21 June
2013.
Citation: Rosen EM (2013) BRCA1 in
the DNA damage response and at telom-
eres. Front. Genet. 4:85. doi: 10.3389/
fgene.2013.00085
This article was submitted to Frontiers in
Cancer Genetics, a specialty of Frontiers
in Genetics.
Copyright © 2013 Rosen. This is an
open-access article distributed under
the terms of the Creative Commons
Attribution License, which permits use,
distribution and reproduction in other
forums, provided the original authors
and source are credited and subject to any
copyright notices concerning any third-
party graphics etc.
Frontiers in Genetics | Cancer Genetics June 2013 | Volume 4 | Article 85 | 14
